Solute carrier family 35 member E2A (SLC35E2A)

Solute carrier family 35 member E2A (SLC35E2A) is classified as a putative nucleotide-sugar transporter and is part of the SLC35 family, specifically subfamily E, which encompasses several predicted or poorly characterized transporters[1][4]. The protein is a multi-pass membrane protein, likely localized to cellular membranes. However, SLC35E2A is primarily annotated as a pseudogene[1], and there is no definitive evidence of its protein product or transport activity in vivo. There is very limited functional, expression, or disease association data specific to SLC35E2A, with no reports of established biological roles, involvement in human diseases, or therapeutic targeting. Additionally, some resources group SLC35E2A with SLC35E2, which is distinct; SLC35E2A appears to be either an uncharacterized gene, a pseudogene, or possibly a misannotation, further limiting its status as a true biomedical target[1]. Key supporting points: - SLC35E2A is annotated as a **pseudogene** and is not currently recognized as a validated or functional transporter in humans[1]. - Unlike other SLC35 family members (such as SLC35A2), **no biological functions, disease links, or interacting drugs have been established for SLC35E2A**. - Its primary aliases include multiple *gene prediction* notations and previous identifiers. - There is a potential for **misannotation** or confusion with SLC35E2, which is also cited as a pseudogene or poorly characterized in major databases[1]. In summary, SLC35E2A does **not meet criteria for an established therapeutic target** due to its pseudogene status, lack of functional data, and absence from key pharmacological and disease association resources[1][4].

Other names

FLJ34996FLJ44537KIAA0447MGC104754MGC117254MGC126715MGC138494DKFZp686M0869SLC35E2SLC35E2APSLC35E2P